Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (19 quarters reported)
$1.09B in Q4 2021 → $881M now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Kymera Therapeutics, Inc. | 37.1% | Trimmed 38% | 2,847,541 | $327M |
| Dyne Therapeutics, Inc. | 17.1% | Trimmed 26% | 6,800,099 | $151M |
| Sionna Therapeutics, Inc. | 15.0% | Unchanged | 2,995,602 | $132M |
| Kailera Therapeutics, Inc. | 12.9% | New | 5,171,282 | $114M |
| Disc Medicine, Inc. | 12.6% | Unchanged | 1,513,875 | $111M |
| Q32 Bio, Inc. | 3.9% | Added 30% | 2,717,106 | $34.6M |
| Korro Bio, Inc. | 1.4% | Trimmed 15% | 962,884 | $12.7M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended June 30, 2026 · filed August 13, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Kymera Therapeutics, Inc. | Trimmed | −1,730,467 | −$198M | 37.1% |
| Kailera Therapeutics, Inc. | New | +5,171,282 | +$114M | 12.9% |
| Dyne Therapeutics, Inc. | Trimmed | −2,330,366 | −$51.8M | 17.1% |
| Q32 Bio, Inc. | Added | +625,000 | +$7.96M | 3.9% |
| Korro Bio, Inc. | Trimmed | −174,265 | −$2.3M | 1.4% |
quarter ended March 31, 2026 · filed May 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Day One Biopharmaceuticals, Inc. | Exited | −6,412,560 | −$59.8M | — |
| Kymera Therapeutics, Inc. | Trimmed | −81,866 | −$6.82M | 48.3% |
| Generation Bio, Co. | Exited | −827,946 | −$4.7M | — |
quarter ended December 31, 2025 · filed February 13, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Disc Medicine, Inc. | Trimmed | −628,742 | −$49.9M | 13.9% |
| Sionna Therapeutics, Inc. | Trimmed | −619,925 | −$25.5M | 14.2% |
| Kymera Therapeutics, Inc. | Trimmed | −236,588 | −$18.4M | 41.9% |
| Generation Bio, Co. | Exited | −827,946 | −$5.07M | — |
| Generation Bio, Co. | New | +827,946 | +$4.7M | 0.5% |
| Imagenebio, Inc. | Exited | −377,814 | −$3.08M | — |
| Day One Biopharmaceuticals, Inc. | Trimmed | −17,697 | −$165K | 6.9% |
quarter ended September 30, 2025 · filed November 13, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Third Harmonic Bio, Inc. | Exited | −10,402,286 | −$56.5M | — |
| Vigil Neuroscience, Inc. | Exited | −5,836,874 | −$46.4M | — |
| Generation Bio, Co. | Trimmed | −7,451,538 | −$45.6M | 0.7% |
| Disc Medicine, Inc. | Trimmed | −241,839 | −$16M | 18.8% |
| IO Ikena Oncology, Inc. | Exited | −5,018,178 | −$6.72M | — |
| Imagenebio, Inc. | New | +377,814 | +$3.08M | 0.4% |
| Sionna Therapeutics, Inc. | Trimmed | −78,493 | −$2.31M | 14.1% |
quarter ended June 30, 2025 · filed August 12, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| AT Aerovate Therapeutics, Inc. | Exited | −1,799,232 | −$4.52M | — |
| Spero Therapeutics, Inc. | Exited | −305,255 | −$220K | — |
quarter ended March 31, 2025 · filed May 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Sionna Therapeutics, Inc. | New | +3,694,020 | +$38.6M | 7.4% |
| Dyne Therapeutics, Inc. | Added | +1,111,111 | +$11.6M | 18.3% |
| Disc Medicine, Inc. | Trimmed | −125,000 | −$6.21M | 22.7% |
| TT Tectonic Therapeutics, Inc. | Exited | −78,447 | −$3.62M | — |
quarter ended December 31, 2024 · filed February 06, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| TT Tectonic Therapeutics, Inc. | Trimmed | −300,000 | −$13.9M | 0.4% |
| Third Harmonic Bio, Inc. | Trimmed | −505,573 | −$5.2M | 13.1% |
| Dianthus Therapeutics, Inc. | Exited | −76,979 | −$2.11M | — |
| Spero Therapeutics, Inc. | Trimmed | −97,630 | −$101K | — |
| Dyne Therapeutics, Inc. | Trimmed | −782 | −$18.4K | 23.1% |
quarter ended September 30, 2024 · filed November 13, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Kymera Therapeutics, Inc. | Trimmed | −453,960 | −$21.5M | 21.5% |
| Replimune Group, Inc. | Exited | −2,098,300 | −$18.9M | — |
| Dianthus Therapeutics, Inc. | Trimmed | −60,000 | −$1.64M | 0.2% |
| Spero Therapeutics, Inc. | Trimmed | −132,451 | −$177K | 0.1% |
Loading...
